KMT2D (O14686) variants and mutations
KMT2D (also known as O14686) is a human protein-coding gene encoding a histone-lysine N-methyltransferase 2D protein. It deposits enhancer-associated H3K4 methylation and coordinates developmental gene expression through chromatin regulatory complexes. Heterozygous loss-of-function variants are a major cause of Kabuki syndrome, and somatic mutations are common in several lymphomas and solid tumors. This analysis covers 21,573 KMT2D variants and mutations. Of these, 35% have computational variant effect predictions. Disease context includes Kabuki syndrome, Kabuki syndrome 1, and choanal atresia-athelia-hypothyroidism-delayed puberty-short stature syndrome. Example KMT2D variants include M1T, D2E, and D2H.
Variant analysis overview
- Gene: KMT2D
- Protein: O14686
- UniProt accession: O14686
- Organism: Homo sapiens
- Variants analyzed: 21573
- Variant scope: all variants
- Completed: 2026-08-22
Variant and mutation evidence
- Variant composition: 21,410 unspecified-consequence records; 3 stop lost; 95 synonymous variants; 55 missense variants; 3 splice-region variants; 7 frameshift variants; 2 stop-gained variants; 1 in-frame deletions; 1 substitution
- Prediction scores: 7,568 variants have prediction scores (35% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Kabuki syndrome, Kabuki syndrome 1, choanal atresia-athelia-hypothyroidism-delayed puberty-short stature syndrome, diffuse large B-cell lymphoma, head and neck squamous cell carcinoma, prostate adenocarcinoma, squamous cell lung carcinoma, medulloblastoma, hereditary disease, urinary bladder cancer, cervical squamous cell carcinoma, Intellectual disability.
Protein structure and variant hotspots
- Protein features: 4 domains; 6 binding sites; 38 post-translational modification sites.
- Structural context: 1,251 variants have structural context.
- PTM context: 155 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable KMT2D variants
Examples include M1T, D2E, D2H, D2Y, S3G, S3I, S3N, S3R. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1T (p.Met1Thr), rs1057520167, ClinGen CA16603307, ClinVar RCV000444887, MetaLR 0.71, MetaSVM 0.56, Likely pathogenic
- D2E (p.Asp2Glu), rs1197278365, ClinGen CA384691482, ClinVar RCV002720703, TOPMed rs1197278365, REVEL 0.28, MetaLR 0.37, Benign, Kabuki syndrome
- D2H (p.Asp2His), Ensembl rs2120718673
- D2Y (p.Asp2Tyr), Ensembl rs2120718673
- S3G (p.Ser3Gly), Ensembl rs2120718652
- S3I (p.Ser3Ile), TOPMed rs1451360303, gnomAD rs1451360303
- S3N (p.Ser3Asn), TOPMed rs1451360303, gnomAD rs1451360303, REVEL 0.43, MetaLR 0.20
- S3R (p.Ser3Arg), Ensembl rs2120718620
- S3T (p.Ser3Thr), TOPMed rs1451360303, gnomAD rs1451360303, NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- Q4* (p.Gln4Ter), Ensembl rs2120718610
- Q4E (p.Gln4Glu), Ensembl rs2120718610
- Q4H (p.Gln4His), Ensembl rs2120718594
- Q4K (p.Gln4Lys), Ensembl rs2120718610
- Q4W (p.Gln4Trp), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- K5N (p.Lys5Asn), ExAC rs772489056, gnomAD rs772489056
- K5Q (p.Lys5Gln), NCI-TCGA Cosmic COSV5648, Variant assessed as somatic; moderate impact.
- L6M (p.Leu6Met), Ensembl rs2120718565
- L6Q (p.Leu6Gln), Ensembl rs2120718547
- L6V (p.Leu6Val), Ensembl rs2120718565
- A7D (p.Ala7Asp), Ensembl rs2120718503, Likely benign
- A7G (p.Ala7Gly), Ensembl rs2120718503, Likely benign
- A7P (p.Ala7Pro), ExAC rs748617194, TOPMed rs748617194, gnomAD rs748617194, REVEL 0.39, MetaLR 0.20, Uncertain significance, Choanal atresia-athelia-hypothyroidism-delayed puberty-short stature syndrome; K
- A7S (p.Ala7Ser), ExAC rs748617194, TOPMed rs748617194, gnomAD rs748617194, Uncertain significance
- A7T (p.Ala7Thr), ExAC rs748617194, TOPMed rs748617194, gnomAD rs748617194, Uncertain significance
- A7V (p.Ala7Val), rs2120718503, ClinGen CA384691391, ClinVar RCV002741059, Ensembl rs2120718503, AlphaMissense 0.15, MetaLR 0.26, Likely benign, Kabuki syndrome
- G8A (p.Gly8Ala), Ensembl rs2120718461
- G8C (p.Gly8Cys), Ensembl rs2120718475
- G8D (p.Gly8Asp), Ensembl rs2120718461, REVEL 0.38, MetaLR 0.27
- G8R (p.Gly8Arg), Ensembl rs2120718475
- G8S (p.Gly8Ser), Ensembl rs2120718475, REVEL 0.34, MetaLR 0.23
- E9* (p.Glu9Ter), Ensembl rs2120718432
- E9D (p.Glu9Asp), Ensembl rs2120718410, Likely benign
- E9G (p.Glu9Gly), rs2120718422, ClinGen CA384691348, ClinVar RCV003589645, Ensembl rs2120718422, AlphaMissense 0.37, MetaLR 0.53, Uncertain significance, Kabuki syndrome
- E9K (p.Glu9Lys), Ensembl rs2120718432
- E9Q (p.Glu9Gln), Ensembl rs2120718432
- E9V (p.Glu9Val), Ensembl rs2120718422, Uncertain significance
- D10E (p.Asp10Glu), Ensembl rs2120718383
- D10H (p.Asp10His), Ensembl rs2120718400
- D10N (p.Asp10Asn), NCI-TCGA TCGA novel, Ensembl rs2120718400, Variant assessed as somatic; moderate impact.
- K11E (p.Lys11Glu), rs2498474255, ClinGen CA384691302, ClinVar RCV003842957, Uncertain significance, Kabuki syndrome
- K11N (p.Lys11Asn), rs754250785, ClinGen CA6548821, ClinVar RCV002715222, ExAC rs754250785, REVEL 0.36, MetaLR 0.21, Uncertain significance, Kabuki syndrome
- D12E (p.Asp12Glu), gnomAD rs1227185621
- D12G (p.Asp12Gly), Ensembl rs1938342080
- D12H (p.Asp12His), Ensembl rs2120718350, Uncertain significance
- D12N (p.Asp12Asn), rs2120718350, ClinGen CA384691281, ClinVar RCV003754016, Ensembl rs2120718350, AlphaMissense 0.40, MetaLR 0.62, Uncertain significance, Kabuki syndrome
- D12Y (p.Asp12Tyr), NCI-TCGA Cosmic COSV5641, Variant assessed as somatic; moderate impact.
- S13* (p.Ser13Ter), Ensembl rs2120718294
- S13L (p.Ser13Leu), Ensembl rs2120718294, REVEL 0.35, MetaLR 0.52
- S13T (p.Ser13Thr), Ensembl rs2120718315
- E14* (p.Glu14Ter), Ensembl rs2120718269
- E14D (p.Glu14Asp), Ensembl rs2120718262
- E14K (p.Glu14Lys), Ensembl rs2120718269, REVEL 0.33, MetaLR 0.37
- E14Q (p.Glu14Gln), Ensembl rs2120718269
- P15A (p.Pro15Ala), TOPMed rs1002765819, Uncertain significance
- P15L (p.Pro15Leu), rs756336640, ClinGen CA6548818, ClinVar RCV001995722, ExAC rs756336640, REVEL 0.31, AlphaMissense 0.11, Likely benign, Kabuki syndrome
- P15Q (p.Pro15Gln), rs756336640, ClinGen CA384691219, ClinVar RCV003239240, ExAC rs756336640, AlphaMissense 0.11, MetaLR 0.28, Uncertain significance, not provided
- P15R (p.Pro15Arg), ExAC rs756336640, gnomAD rs756336640, Likely benign
- P15S (p.Pro15Ser), rs1002765819, ClinGen CA236624813, ClinVar RCV001952643, TOPMed rs1002765819, REVEL 0.28, MetaLR 0.26, Uncertain significance, Kabuki syndrome
- A16E (p.Ala16Glu), Ensembl rs2120718184
- A16G (p.Ala16Gly), Ensembl rs2120718184
- A16P (p.Ala16Pro), gnomAD rs1330280764, Benign
- A16S (p.Ala16Ser), rs1330280764, ClinGen CA384691205, ClinVar RCV002775146, gnomAD rs1330280764, REVEL 0.35, MetaLR 0.27, Benign, Kabuki syndrome
- A16T (p.Ala16Thr), NCI-TCGA TCGA novel, gnomAD rs1330280764, Benign
- A16V (p.Ala16Val), Ensembl rs2120718184
- A17G (p.Ala17Gly), rs769271092, ClinGen CA384691049, ClinVar RCV001884268, ExAC rs769271092, REVEL 0.35, MetaLR 0.56, Uncertain significance, Kabuki syndrome
- A17P (p.Ala17Pro), TOPMed rs1323918085, gnomAD rs1323918085, REVEL 0.32, AlphaMissense 0.24, Uncertain significance
- A17T (p.Ala17Thr), rs1323918085, ClinGen CA384691189, ClinVar RCV003752959, TOPMed rs1323918085, AlphaMissense 0.24, MetaLR 0.61, Uncertain significance, Kabuki syndrome
- A17V (p.Ala17Val), ExAC rs769271092, gnomAD rs769271092, REVEL 0.32, MetaLR 0.56, Uncertain significance
- D18Y (p.Asp18Tyr), rs749662138, ClinGen CA6548801, ClinVar RCV002923149, ClinVar RCV005010792, REVEL 0.45, MetaLR 0.60, Conflicting interpretations, Kabuki syndrome 1; Choanal atresia-athelia-hypothyroidism-delayed puberty-short
- P20L (p.Pro20Leu), TOPMed rs963025174, gnomAD rs963025174, REVEL 0.32, MetaLR 0.22, Benign, Kabuki syndrome
- P20R (p.Pro20Arg), TOPMed rs963025174, gnomAD rs963025174
- P20S (p.Pro20Ser), TOPMed rs1938324886
- A21T (p.Ala21Thr), Ensembl rs2120716451, REVEL 0.31, MetaLR 0.26
- A22V (p.Ala22Val), rs1347059574, ClinGen CA384690947, ClinVar RCV002132365, TOPMed rs1347059574, REVEL 0.42, MetaLR 0.24, Benign, Kabuki syndrome
- S23A (p.Ser23Ala), rs779539520, ClinGen CA6548800, ClinVar RCV002591863, ClinVar RCV004536634, REVEL 0.36, MetaLR 0.26, Benign, Kabuki syndrome
- S23F (p.Ser23Phe), rs1938323806, ClinGen CA384690934, NCI-TCGA Cosmic COSV9998, ClinVar RCV002816296, REVEL 0.31, MetaLR 0.37, Uncertain significance, Kabuki syndrome; not provided
- E24* (p.Glu24Ter), rs1555198910, ClinGen CA384690933, ClinVar RCV000622718, Ensembl rs1555198910, CADD 34.00, Likely pathogenic
- E24D (p.Glu24Asp), gnomAD rs1938323460, REVEL 0.37, MetaLR 0.23
- E24G (p.Glu24Gly), Ensembl rs2120716344
- D25E (p.Asp25Glu), ExAC rs756318924, gnomAD rs756318924
- D25H (p.Asp25His), Ensembl rs2120716314
- D25Y (p.Asp25Tyr), Ensembl rs2120716314
- P26A (p.Pro26Ala), Ensembl rs2120716281, REVEL 0.36, MetaLR 0.19
- P26L (p.Pro26Leu), rs2498473186, ClinGen CA384690861, ClinVar RCV002302096, Uncertain significance, Kabuki syndrome
- S27G (p.Ser27Gly), rs1938323081, ClinGen CA384690847, ClinVar RCV001034325, ClinVar RCV004986734, REVEL 0.30, MetaLR 0.22, Benign
- S27N (p.Ser27Asn), rs746049766, ClinGen CA6548798, ClinVar RCV002919150, ClinVar RCV004758894, REVEL 0.39, MetaLR 0.24, Benign, Kabuki syndrome
- S27R (p.Ser27Arg), gnomAD rs1938322675
- A28C (p.Ala28Cys), rs2498473176, ClinGen CA2580086334, ClinVar RCV002875641, Pathogenic
- A28P (p.Ala28Pro), ExAC rs781142081, gnomAD rs781142081
- A28T (p.Ala28Thr), ExAC rs781142081, gnomAD rs781142081, REVEL 0.36, MetaLR 0.19
- A28V (p.Ala28Val), Ensembl rs2120716193
- T29A (p.Thr29Ala), TOPMed rs1938322316
- T29I (p.Thr29Ile), Ensembl rs910120446
- S31L (p.Ser31Leu), rs1448043458, ClinGen CA384690719, ClinVar RCV002003220, gnomAD rs1448043458, REVEL 0.35, MetaLR 0.24, Likely benign, Kabuki syndrome
- S31P (p.Ser31Pro), rs1938321808, ClinGen CA384690737, ClinVar RCV001336574, ClinVar RCV004531124, REVEL 0.32, MetaLR 0.19, Uncertain significance
- D32H (p.Asp32His), rs2120716122, ClinGen CA384690706, ClinVar RCV002276289, Ensembl rs2120716122, REVEL 0.34, MetaLR 0.27, Uncertain significance, not provided
- P34S (p.Pro34Ser), Ensembl rs2120716090
- N35D (p.Asn35Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- N35K (p.Asn35Lys), TOPMed rs1938321127, REVEL 0.26, MetaLR 0.19
- N35S (p.Asn35Ser), ExAC rs757397817, TOPMed rs757397817, gnomAD rs757397817, REVEL 0.34, MetaLR 0.19, Benign, Kabuki syndrome
- P36A (p.Pro36Ala), gnomAD rs954226380, Benign
- P36L (p.Pro36Leu), rs751629550, ClinGen CA6548795, ClinVar RCV003753401, ExAC rs751629550, REVEL 0.23, MetaLR 0.23, Benign, Kabuki syndrome
- P36Q (p.Pro36Gln), ExAC rs751629550, gnomAD rs751629550, Benign
- P36S (p.Pro36Ser), rs954226380, ClinGen CA236624413, ClinVar RCV002049927, ClinVar RCV002543463, REVEL 0.29, MetaLR 0.23, Benign/Likely benign, Kabuki syndrome; Inborn genetic diseases
- P36T (p.Pro36Thr), gnomAD rs954226380, Benign
- H37N (p.His37Asn), TOPMed rs1243381790, gnomAD rs1243381790, REVEL 0.27, MetaLR 0.21, Benign
- H37P (p.His37Pro), rs1409291268, ClinGen CA384690460, ClinVar RCV003590382, Ensembl rs1409291268, AlphaMissense 0.07, MetaLR 0.19, Uncertain significance, Kabuki syndrome
- H37Y (p.His37Tyr), rs1243381790, ClinGen CA384690469, ClinVar RCV000601562, ClinVar RCV002528802, REVEL 0.31, MetaLR 0.20, Benign
- V38L (p.Val38Leu), gnomAD rs1441543137, REVEL 0.27, MetaLR 0.18
- G39R (p.Gly39Arg), ExAC rs753608064, TOPMed rs753608064, gnomAD rs753608064, REVEL 0.40, MetaLR 0.38, Likely benign, Kabuki syndrome
- G39V (p.Gly39Val), TOPMed rs1213390684
- E40D (p.Glu40Asp), rs1339776566, ClinGen CA384690353, ClinVar RCV003843919, ClinVar RCV005013239, REVEL 0.34, MetaLR 0.27, Conflicting interpretations, Kabuki syndrome; Choanal atresia-athelia-hypothyroidism-delayed puberty-short st
- V41F (p.Val41Phe), TOPMed rs1938318494, gnomAD rs1938318494, REVEL 0.39, MetaLR 0.28
- V41G (p.Val41Gly), Ensembl rs2120715831
- V41L (p.Val41Leu), TOPMed rs1938318494, gnomAD rs1938318494
- S42F (p.Ser42Phe), rs1555198886, ClinGen CA384690291, ClinVar RCV000505820, Ensembl rs1555198886, AlphaMissense 0.13, MetaLR 0.38, Likely pathogenic
- L44F (p.Leu44Phe), gnomAD rs1229092998, REVEL 0.36, MetaLR 0.22
- L44H (p.Leu44His), Ensembl rs2120715759
- S45G (p.Ser45Gly), ExAC rs760258777, TOPMed rs760258777, gnomAD rs760258777, REVEL 0.30, MetaLR 0.23
- S46C (p.Ser46Cys), rs2120715696, ClinGen CA384690127, ClinVar RCV002222819, ClinVar RCV003152787, AlphaMissense 0.09, MetaLR 0.37, Uncertain significance, Kabuki syndrome 1; not provided
- G47E (p.Gly47Glu), rs1453779890, ClinGen CA384690115, ClinVar RCV004411909, TOPMed rs1453779890, AlphaMissense 0.11, MetaLR 0.25, Uncertain significance, Inborn genetic diseases
- G47R (p.Gly47Arg), TOPMed rs1938317391, REVEL 0.31, MetaLR 0.36
- G47W (p.Gly47Trp), TOPMed rs1938317391
- S48R (p.Ser48Arg), Ensembl rs2120715648
- P49A (p.Pro49Ala), ESP rs372067643, ExAC rs372067643, TOPMed rs372067643, gnomAD rs372067643, Benign
- P49R (p.Pro49Arg), gnomAD rs1447372379, REVEL 0.26, MetaLR 0.22
- P49T (p.Pro49Thr), rs372067643, ClinGen CA6548789, ClinVar RCV003588093, ClinVar RCV005013016, REVEL 0.23, MetaLR 0.20, Benign/Likely benign, Choanal atresia-athelia-hypothyroidism-delayed puberty-short stature syndrome; K
- R50G (p.Arg50Gly), TOPMed rs1360034258, gnomAD rs1360034258, REVEL 0.25, MetaLR 0.25
- L51V (p.Leu51Val), Ensembl rs2120715573
- Q52* (p.Gln52Ter), NCI-TCGA Cosmic COSV9997, Variant assessed as somatic; high impact.
- Q52E (p.Gln52Glu), Ensembl rs2120715556
- Q52R (p.Gln52Arg), rs1565825639, ClinGen CA384689914, ClinVar RCV003864241, Ensembl rs1565825639, REVEL 0.31, MetaLR 0.38, Benign, Kabuki syndrome
- E53D (p.Glu53Asp), TOPMed rs997893922
- T54I (p.Thr54Ile), gnomAD rs1187636945, REVEL 0.38, AlphaMissense 0.07, Benign, Kabuki syndrome
- T54S (p.Thr54Ser), rs1187636945, ClinGen CA384689805, ClinVar RCV003057651, AlphaMissense 0.07, MetaLR 0.28, Uncertain significance, Kabuki syndrome
- P55L (p.Pro55Leu), ExAC rs767274089, TOPMed rs767274089, gnomAD rs767274089, REVEL 0.31, MetaLR 0.24
- P55S (p.Pro55Ser), rs1314970592, ClinGen CA384689771, ClinVar RCV002008566, TOPMed rs1314970592, REVEL 0.39, MetaLR 0.25, Benign, Kabuki syndrome
- Q56* (p.Gln56Ter), rs1592162790, ClinGen CA384689736, NCI-TCGA Cosmic COSV5644, ClinVar RCV001029731, AlphaMissense 0.07, MetaLR 0.26, Pathogenic
- Q56E (p.Gln56Glu), Ensembl rs1592162790, Pathogenic
- Q56R (p.Gln56Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- D57E (p.Asp57Glu), Ensembl rs2120715422
- C58F (p.Cys58Phe), rs2120715393, ClinGen CA384689618, ClinVar RCV003047897, REVEL 0.34, MetaLR 0.27, Uncertain significance, Kabuki syndrome
- C58R (p.Cys58Arg), rs955948792, ClinGen CA236624350, ClinVar RCV002843418, Ensembl rs955948792, REVEL 0.28, MetaLR 0.21, Uncertain significance, Kabuki syndrome
- C58Y (p.Cys58Tyr), Ensembl rs2120715393
- S59G (p.Ser59Gly), rs1555198862, ClinGen CA384689589, ClinVar RCV000545685, ClinVar RCV004537958, AlphaMissense 0.08, MetaLR 0.33, Likely pathogenic
- S59R (p.Ser59Arg), Ensembl rs2120713745
- G60R (p.Gly60Arg), Ensembl rs2120713714
- G60V (p.Gly60Val), TOPMed rs1421460851, gnomAD rs1421460851, REVEL 0.28, MetaLR 0.20
- G60W (p.Gly60Trp), Ensembl rs2120713714
- G61A (p.Gly61Ala), Ensembl rs2120713633
- G61C (p.Gly61Cys), TOPMed rs1938304119, gnomAD rs1938304119, REVEL 0.34, MetaLR 0.26, Likely benign
- G61D (p.Gly61Asp), Ensembl rs2120713633
- G61R (p.Gly61Arg), TOPMed rs1938304119, gnomAD rs1938304119, Likely benign
- G61S (p.Gly61Ser), rs1938304119, ClinGen CA384689395, ClinVar RCV001336043, ClinVar RCV003120561, REVEL 0.32, MetaLR 0.23, Likely benign
- G61V (p.Gly61Val), Ensembl rs2120713633
- P62A (p.Pro62Ala), Ensembl rs2120713618
- P62L (p.Pro62Leu), rs371342351, ClinGen CA6548774, ClinVar RCV000578142, ClinVar RCV003753126, REVEL 0.19, MetaLR 0.24, Benign
- P62Q (p.Pro62Gln), ESP rs371342351, ExAC rs371342351, TOPMed rs371342351, gnomAD rs371342351, Benign
- P62R (p.Pro62Arg), ESP rs371342351, ExAC rs371342351, TOPMed rs371342351, gnomAD rs371342351, Benign
- P62S (p.Pro62Ser), Ensembl rs2120713618
- V63A (p.Val63Ala), rs886049488, ClinGen CA10632940, ClinVar RCV003131401, TOPMed rs886049488, REVEL 0.30, MetaLR 0.25, Uncertain significance, not provided
- V63E (p.Val63Glu), TOPMed rs886049488, gnomAD rs886049488, Uncertain significance
- V63G (p.Val63Gly), TOPMed rs886049488, gnomAD rs886049488, Uncertain significance
- V63L (p.Val63Leu), rs767327365, ExAC rs767327365, TOPMed rs767327365, gnomAD rs767327365, REVEL 0.30, MetaLR 0.25, Likely benign, Kabuki syndrome
- V63M (p.Val63Met), ExAC rs767327365, TOPMed rs767327365, gnomAD rs767327365, REVEL 0.24, MetaLR 0.29, Likely benign
- R64G (p.Arg64Gly), ExAC rs761525910, TOPMed rs761525910, gnomAD rs761525910, Benign
- R64L (p.Arg64Leu), TOPMed rs587778462, Uncertain significance
- R64P (p.Arg64Pro), TOPMed rs587778462, Uncertain significance
- R64Q (p.Arg64Gln), rs587778462, ClinGen CA160533, ClinVar RCV000121393, ClinVar RCV003764845, REVEL 0.31, MetaLR 0.44, Uncertain significance
- R64W (p.Arg64Trp), rs761525910, ClinGen CA6548770, ClinVar RCV003115013, ExAC rs761525910, REVEL 0.49, MetaLR 0.51, Benign, Kabuki syndrome
- R65C (p.Arg65Cys), rs1189364625, ClinGen CA384689291, ClinVar RCV002613342, ClinVar RCV004529159, REVEL 0.41, MetaLR 0.34, Conflicting interpretations, KMT2D-related disorder; Kabuki syndrome
- R65H (p.Arg65His), rs763644658, ClinGen CA6548768, ClinVar RCV002633360, ExAC rs763644658, REVEL 0.37, MetaLR 0.27, Benign, Kabuki syndrome
- R65L (p.Arg65Leu), ExAC rs763644658, gnomAD rs763644658, Benign
- R65P (p.Arg65Pro), ExAC rs763644658, gnomAD rs763644658, Benign
- R65S (p.Arg65Ser), rs1189364625, ClinGen CA384689298, ClinVar RCV002008555, TOPMed rs1189364625, REVEL 0.44, MetaLR 0.26, Uncertain significance, Kabuki syndrome
- C66* (p.Cys66Ter), gnomAD rs1177637771
- C66S (p.Cys66Ser), Ensembl rs2120713354
- C66W (p.Cys66Trp), gnomAD rs1177637771
- C66Y (p.Cys66Tyr), Ensembl rs2120713354
- A67G (p.Ala67Gly), ExAC rs763380529, gnomAD rs763380529, Likely benign
Public KMT2D analysis runs
- KMT2D analysis run — KMT2D (21,573 variants) — completed 2026-08-22